Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
32.75
-0.32 (-0.97%)
May 8, 2025, 4:00 PM EDT - Market closed
Ionis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for Ionis Pharmaceuticals stock have an average target of 57.41, with a low estimate of 37 and a high estimate of 77. The average target predicts an increase of 75.30% from the current stock price of 32.75.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Ionis Pharmaceuticals stock from 18 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 7 | 7 |
| Buy | 7 | 7 | 7 | 6 | 4 | 4 |
| Hold | 5 | 5 | 5 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 18 | 18 | 19 | 19 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $65 → $64 | Strong Buy | Maintains | $65 → $64 | +95.42% | May 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $45 → $50 | Strong Buy | Maintains | $45 → $50 | +52.67% | May 1, 2025 |
| Needham | Needham | Strong Buy Maintains $60 → $55 | Strong Buy | Maintains | $60 → $55 | +67.94% | Apr 30, 2025 |
| Needham | Needham | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +83.21% | Apr 15, 2025 |
| Needham | Needham | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +83.21% | Apr 8, 2025 |
Financial Forecast
Revenue This Year
675.67M
from 705.14M
Decreased by -4.18%
Revenue Next Year
860.74M
from 675.67M
Increased by 27.39%
EPS This Year
-3.90
from -3.04
EPS Next Year
-3.11
from -3.90
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 841.1M | 1.1B | 1.7B | ||
| Avg | 675.7M | 860.7M | 1.2B | ||
| Low | 585.3M | 661.6M | 395.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 19.3% | 64.3% | 96.5% | ||
| Avg | -4.2% | 27.4% | 38.1% | ||
| Low | -17.0% | -2.1% | -54.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.24 | -2.22 | -0.63 | ||
| Avg | -3.90 | -3.11 | -1.60 | ||
| Low | -4.20 | -4.17 | -2.34 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.